This is a re-posting of a message from an other member.
Had to re-post it, since it is a good one. Could not find the messenger- handle now.
But ...oh so true !
NEMO
I just got the following from the company:
Currently both of these products are still protected by patents until early next year (in most cases; varies country by country). However, by obtaining marketing authorization, we have overcome the hardest obstacle in our way from benefiting from these products. After receiving market authorization we are able to sell these products the moment they are off patent.
We are currently building up our sales force, but the one benefit of selling generic products is that a large sale force is not needed, which will really help manage the selling, general and admin expenses related to these products (as hospitals already know what the product does, and are just competing on price). Given we received market authorization prior to the products coming off patent, our goal is to be one of the first to market which will lead us to obtain a higher market share. In terms of volumes, both Bortezomib and Pemetrexed are close to a billion dollar market.
for 2020 they will still have a small income but this can explode in 2021